CN1688576A - 噻吩化合物 - Google Patents

噻吩化合物 Download PDF

Info

Publication number
CN1688576A
CN1688576A CNA038237555A CN03823755A CN1688576A CN 1688576 A CN1688576 A CN 1688576A CN A038237555 A CNA038237555 A CN A038237555A CN 03823755 A CN03823755 A CN 03823755A CN 1688576 A CN1688576 A CN 1688576A
Authority
CN
China
Prior art keywords
formula
compound
thiophene
group
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038237555A
Other languages
English (en)
Chinese (zh)
Inventor
C·W·安德鲁斯三世
M·张
R·G·达维斯－瓦德
D·H·德鲁里
K·A·埃米特
R·D·胡巴德
K·W·昆茨
J·A·林
R·A·小穆克
G·K·史密斯
J·M·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1688576A publication Critical patent/CN1688576A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038237555A 2002-08-08 2003-08-04 噻吩化合物 Pending CN1688576A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40200802P 2002-08-08 2002-08-08
US60/402,008 2002-08-08

Publications (1)

Publication Number Publication Date
CN1688576A true CN1688576A (zh) 2005-10-26

Family

ID=31715769

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038237555A Pending CN1688576A (zh) 2002-08-08 2003-08-04 噻吩化合物

Country Status (18)

Country Link
US (2) US20060074119A1 (enExample)
EP (1) EP1546137A1 (enExample)
JP (1) JP2006505522A (enExample)
KR (1) KR20050071471A (enExample)
CN (1) CN1688576A (enExample)
AU (1) AU2003265348B2 (enExample)
BR (1) BR0313160A (enExample)
CA (1) CA2493908A1 (enExample)
IL (1) IL166328A0 (enExample)
IS (1) IS7657A (enExample)
MA (1) MA27427A1 (enExample)
MX (1) MXPA05001544A (enExample)
NO (1) NO20050525L (enExample)
NZ (1) NZ538134A (enExample)
PL (1) PL375532A1 (enExample)
RU (1) RU2296758C2 (enExample)
WO (1) WO2004014899A1 (enExample)
ZA (1) ZA200500864B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256972A (zh) * 2008-12-18 2011-11-23 霍夫曼-拉罗奇有限公司 噻唑基-苯并咪唑类
CN103408540A (zh) * 2013-08-22 2013-11-27 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7521448B2 (en) * 2003-08-21 2009-04-21 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-Kit inhibitors
WO2005037827A1 (en) * 2003-10-16 2005-04-28 Smithkline Beecham Corporation Process for preparing benzimidazole thiophenes
TW200524575A (en) * 2003-10-27 2005-08-01 S Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
CA2549869C (en) 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
US7560568B2 (en) 2004-01-28 2009-07-14 Smithkline Beecham Corporation Thiazole compounds
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2577947A1 (en) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. Novel substituted imidazole derivative
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
CN101115749B (zh) 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
ATE459620T1 (de) * 2005-09-06 2010-03-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk- modulatoren
US7595330B2 (en) * 2005-09-06 2009-09-29 Smithkline Beecham Corporation Benzimidazole thiophene compounds
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
WO2007030366A1 (en) * 2005-09-06 2007-03-15 Smithkline Beecham Corporation Regioselective process for preparing benzimidazole thiophenes
WO2007087283A2 (en) * 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US7504513B2 (en) * 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US7829590B2 (en) 2006-04-13 2010-11-09 Guy Brenchley Thiophene-carboxamides useful as inhibitors of protein kinases
US7851495B2 (en) 2006-05-23 2010-12-14 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2027116A2 (en) 2006-05-23 2009-02-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
ATE469894T1 (de) * 2006-06-02 2010-06-15 Glaxosmithkline Llc Benzimidazol-substituierte thiophenderivate mit wirkung auf plk
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
EP2032564A2 (en) * 2006-06-02 2009-03-11 SmithKline Beecham Corporation Substituted benzimidazole thiophene benzyl ether compounds
MX2009000456A (es) 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US20100056525A1 (en) * 2006-10-31 2010-03-04 Tara Renae Rheault 5- and 6- substituted benzimidazole thiophene compounds
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
JP2010531887A (ja) * 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
WO2009003911A1 (en) * 2007-06-29 2009-01-08 4Sc Ag Thiophene-imidazopyridines
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
RU2501787C2 (ru) * 2007-11-02 2013-12-20 Метилджен Инк. Ингибиторы гистондеацетилазы
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
MY161598A (en) * 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
JP5841548B2 (ja) 2010-02-17 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法及び使用
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
PH12013500723A1 (en) 2010-10-13 2017-08-23 Millennium Pharm Inc Heteroaryls and uses thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2014007805A0 (en) * 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
US9018380B2 (en) 2012-08-24 2015-04-28 Boar of Regents, The University of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2852054T3 (es) * 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
PL3880654T3 (pl) 2018-11-19 2022-04-25 Global Blood Therapeutics, Inc. Związki 2-formylo-3-hydroksyfenyloksymetylowe zdolne do modulowania hemoglobiny
CN119707936B (zh) * 2025-02-25 2025-07-25 中南大学 一种2,4-二取代-5-氟嘧啶衍生物的盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859648A (en) * 1984-12-28 1989-08-22 Mobil Oil Corporation Layered metal chalcogenides containing interspathic polymeric chalcogenides
FR2600000B1 (fr) * 1986-06-13 1989-04-14 Extramet Sa Procede et dispositif de granulation d'un metal fondu
US4818270A (en) * 1986-08-28 1989-04-04 Monsanto Company 2-(Heteroamino)-4,5-substituted-oxazole/thiazole compounds as herbicide antidotes, compositions and use
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US5151424A (en) * 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US5342957A (en) * 1988-11-29 1994-08-30 Janssen Pharmaceutica N.V. Benzimidazoles useful in treating epithelial disorders
US5633273A (en) * 1991-03-28 1997-05-27 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd] indoles
US5457102A (en) * 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en) * 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
EP1001767A4 (en) * 1997-06-04 2001-07-04 Lilly Co Eli ANTIVIRAL CONNECTIONS
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2000012089A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6358738B1 (en) * 1998-05-13 2002-03-19 The President And Fellows Of Harvard College Polo box therapeutic compositions, methods, and uses therefor
RU2224762C2 (ru) * 1998-07-16 2004-02-27 Авентис Фарма Дойчланд Гмбх Производные фосфиновых и фосфоновых кислот, способ их получения и фармацевтическая композиция на их основе
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
US6642425B2 (en) * 2002-03-05 2003-11-04 Sasol North America Inc. Reactive distillation process for the alkylation of aromatic hydrocarbons
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256972A (zh) * 2008-12-18 2011-11-23 霍夫曼-拉罗奇有限公司 噻唑基-苯并咪唑类
CN103408540A (zh) * 2013-08-22 2013-11-27 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途

Also Published As

Publication number Publication date
NO20050525L (no) 2005-05-06
JP2006505522A (ja) 2006-02-16
NZ538134A (en) 2006-03-31
US20060074119A1 (en) 2006-04-06
ZA200500864B (en) 2006-04-26
IS7657A (is) 2005-01-20
AU2003265348B2 (en) 2007-08-16
US20080269298A1 (en) 2008-10-30
EP1546137A1 (en) 2005-06-29
WO2004014899A1 (en) 2004-02-19
IL166328A0 (en) 2006-01-15
RU2296758C2 (ru) 2007-04-10
KR20050071471A (ko) 2005-07-07
AU2003265348A1 (en) 2004-02-25
RU2005102390A (ru) 2006-01-10
PL375532A1 (en) 2005-11-28
MA27427A1 (fr) 2005-07-01
BR0313160A (pt) 2005-07-12
CA2493908A1 (en) 2004-02-19
MXPA05001544A (es) 2005-04-19

Similar Documents

Publication Publication Date Title
CN1688576A (zh) 噻吩化合物
ES2325440T3 (es) Compuestos de pirimidina.
CN1234693C (zh) 抑制蛋白激酶的吲唑化合物和药物组合物及它们的应用
CN1189467C (zh) 药学活性磺酰胺衍生物
CN1976907A (zh) 杂环酰胺化合物及其作为mmp－13抑制剂的用途
CN101080396A (zh) 作为B－Raf抑制剂的喹喔啉
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN101048388A (zh) 喹唑啉酮衍生物及其作为B－Raf抑制剂的用途
CN1585754A (zh) 用作抗肿瘤药物的喹唑啉衍生物
CN1135224C (zh) 苯并咪唑衍生物
CN1826324A (zh) 吲唑、苯并异噁唑和苯并异噻唑激酶抑制剂
CN1886378A (zh) 用于治疗增殖性疾病的用作raf激酶抑制剂的1,4－二取代的异喹啉衍生物
CA2383546A1 (en) Src kinase inhibitor compounds
CN1503673A (zh) 消炎药
CN1933830A (zh) 吲哚衍生物和其作为激酶抑制剂特别是ikk2抑制剂的用途
CN1780822A (zh) 2,4－二氢－[1,2,4]三唑－3－硫酮衍生物作为酶髓过氧化物酶(mpo)抑制剂的用途
JP2007519720A (ja) チアゾール化合物
US7615643B2 (en) Benzimidazole thiophene compounds
CN1412181A (zh) 抑制整联蛋白与其受体结合的羧酸衍生物
CN1729175A (zh) 四氢喹啉衍生物
JP2009539771A (ja) 置換ベンゾイミダゾールチオフェンベンジルエーテル化合物
CN1859912A (zh) Akt活性的抑制剂
CN1905884A (zh) 用作受体酪氨酸激酶抑制剂的吡唑衍生物
CN1784401A (zh) 新型稠合三唑酮及其用途
CN1688579A (zh) 具有tie2(tek)活性的稠合吡啶和嘧啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051026